New Joint Venture Targets Patient Access
On April 14, 2026, Wellgistics Health, Inc., a Nasdaq-listed company under the ticker WGRX, announced a joint venture with Kare PharmTech’s subsidiary, KareRx Hub, LLC. The collaboration aims to expand access to pharmaceuticals for over 200,000 patients by integrating Wellgistics’ Hub technology with KareRx’s digital platform.
This joint venture formalizes the earlier non-binding letter of intent between the companies. By aligning their technology platforms and operational teams, they accelerate patient access and improve the efficiency of pharmaceutical commercialization. The integration leverages Wellgistics’ proprietary platforms, EinsteinRx™ and HubRx AI™, with KareRx’s AI-driven digital hub.
Prashant Patel, CEO of Wellgistics Health, commented, “This joint venture reflects our continued focus on building an integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies.”
Enhanced Operational Efficiency
The partnership aligns clinical, operational, and commercial teams, allowing for seamless coordination between healthcare providers, pharmacies, and patients. It supports eligibility and benefits verification, prior authorisation workflows, prescription routing, and direct-to-patient fulfillment. As a result, the initiative enhances the national footprint of independent pharmacies, provider networks, and telehealth channels.
Mital Panera, CEO of KareRx, stated, “KareRx was developed to connect providers, pharmacies, and patients through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics’ technology stack, pharma expertise, and operational infrastructure.”
The integrated platform supports pharmaceutical manufacturers and healthcare stakeholders in navigating access pathways more effectively. It strengthens direct-to-patient and decentralized care models, providing pharmaceutical manufacturers with an all-encompassing platform that integrates access, affordability, and fulfillment.
The potential reach of this combined ecosystem is significant, with an estimated 200,000 patient lives benefiting from the collaboration. The initiative requires customary implementation steps, and full integration is expected to take time. However, the partnership positions both companies at the forefront of technological innovation in healthcare.
